Revenue

A Somerville clinic is tackling the crisis of fragmented specialty pet care by adding an in-house cardiologist, promising faster and more integrated treatment.

The leading financial advisor resource rebrands, signaling a major shift beyond digital media to dominate events, research, and education.

With a $30M Series A boost, Ventaris Surgical is developing a new system to solve a persistent problem in urology: incomplete kidney stone removal.

New clinical data suggests a more convenient option for cancer patients, potentially eliminating a return trip to the clinic for a key supportive care drug.

IDEXX prepares to release its 2025 results, with all eyes on whether its high-tech product launches can sustain momentum in a complex pet care market.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

LMU's College of Business Administration celebrates 100 years with partner Office Beacon, blending a legacy of ethical leadership with a focus on innovation.

A new report reveals a paradoxical trend: plaintiff firms are filing fewer securities lawsuits but securing record-breaking, multi-million dollar settlements.

The brand's new non-toxic, fine-fragrance Scent Boosters aim to transform laundry from a chore into a luxurious ritual with lasting, high-tech scents.

Debuting at CES 2026, Guide Sensmart's ApexVision technology promises an 'Ultra-Clarity Era' by solving long-standing issues in thermal imaging.

Sangbo Sim, a long-time LG executive, takes the financial helm at ZKW, a strategic move poised to merge premium lighting with LG's smart mobility vision.

Xueersi.com's award-winning AI Buddy isn't just a smart toy. It's an emotional companion that understands feelings, marking a new era for child development.

Chinese manufacturer Bosuer unveils a diverse lineup of electric dirt bikes at CES, from the beginner-friendly S5 to the high-performance E72.

As retailers face a perfect storm of market pressures, Blue Yonder's new AI agents aim to unify planning and execution, promising greater profits and agility.

After a decade of research, a promising drug for Fragile X syndrome enters a key trial, offering hope for the first-ever targeted treatment for the disorder.

With final approval for its C$3.3 billion acquisition by GTCR, Dentalcorp's move to private ownership is set to reshape Canada's dental landscape.

Gartner names Informatica a Leader in data governance, highlighting the critical need for trusted data foundations in an era of explosive AI growth.

Alto's ambitious high-speed rail plan is moving forward, with the Montréal-Ottawa line as its first phase. Public consultations are set to begin this month.

Marriott Bonvoy inks a massive deal with the ICC, aiming to connect its 260M members with cricket's 2B+ fans through exclusive, once-in-a-lifetime experiences.

As its single-dose glaucoma therapy nears trials, Diorasis adds a seasoned dealmaker to its board, signaling a strategic shift toward market entry.